Stock screenerAll disclosures →
EDGAR →
CUE
Conviction 80HealthcareScan · Thu, Sep 24, 2026Cue Biopharma, Inc. (CUE) closed at $33.39 (+5.30%) on Sep 24, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 56, RS Rating 99, -11.8% from its 52-week high, +229.9% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
CUE$33.39+5.30%
ResistanceSupportVol 14Insider buyInsider sell9
2
Vol MA14 556.88K
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price33.39
Change+5.30%
Gap+0.09%
Rel volume—
Avg volume429.81K
Avg $ vol12.95M
SMA 2030.24
SMA 5029.34
SMA 20019.74
Price vs 50+13.81%
Price vs 200+69.11%
MA stackbullish
50/200 cross—
Supertrendup · 27.60
RSI (14)56
MACD hist0.22
MACD cross—
Stoch %K / %D54 / 46
ADX (14)16
+DI / −DI24 / 21
RSI divergence—
MACD divergence—
ATR %13.79%
ADR %14.23%
52w high37.84
52w low5.31
From 52w high-11.76%
Above 52w low+528.81%
New 52w highNo
SqueezeOff
Bollinger width42.45%
%B0.75
Donchian pos54.18%
Donchian high41.50
Donchian low23.80
AVWAP (52w high)30.27
vs AVWAP high+10.32%
AVWAP (52w low)25.26
vs AVWAP low+32.21%
OBV trendFlat
Chaikin MF (20)-0.05
Today vs 20d—
Avg vol (14d)556.88K
Avg vol (20d)429.81K
Avg $ vol (20d)12.95M
Market cap242.56M
RS Rating99 / 99
RS 3m (vs SPY)+26.24%
RS 6m (vs SPY)+304.45%
RS line new highNo
Trend template8/8
Technical rank97.0
1 week-11.76%
1 month+24.78%
3 months+30.74%
6 months+321.27%
1 year+56.85%
YTD+229.88%
P/E-9.12
P/B105.00
P/S8.83
P/FCF-11.09
EPS-0.2800
Div yield—
ROE—
ROA-86.63%
Debt/Eq1.73
Current1.25
EV/EBITDA-8.95
Gross margin—
Net margin-96.85%
Rev growth195.75%
EPS growth34.60%
Price target83.00
Target upside148.58%
Analyst ratingBuy
Institutional23.86%
Ent. value229.17M
Revenue7.88M
Net income-153.07M
Gross profit—
Free cash flow-21.86M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out4.2M
Employees29
ListedTue, Jan 2, 2018
Free float94.71M
Float %97.2%
Short interest318.42K
Days to cover1.8d
Short volume65.3%
Squeeze score26 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$13.81
Last surprise—
Setup gradeA
Conviction80 / 100
Pattern quality—
Tech rank97.0 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance38.05
Support23.18
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slideBiopharmadive · Tue, Sep 22, 2026
- Cue Biopharma stock swings after positive CUE-221 Phase 2 data and profit-takingAD HOC NEWS · Tue, Sep 22, 2026
- Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win For CSU With Novel Dual MOASeeking Alpha · Mon, Sep 21, 2026
- B. Riley's Buy Rating on Cue Biopharma (CUE) Highlights Market's High Price-to-Sales ExpectationsGuruFocus · Mon, Sep 21, 2026
- China syndrome? Phase II wins for Cue in CSU, stock melts downBioWorld News · Mon, Sep 21, 2026
- Cue Biopharma (CUE) Shares Drop 31% After Phase 2 Trial Results Despite Promising EfficacyGuruFocus · Mon, Sep 21, 2026
- Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria assetSeeking Alpha · Mon, Sep 21, 2026
- $CUE stock is down 28% today. Here's what we see in our data.Quiver Quantitative · Mon, Sep 21, 2026
- What's Going on With Cue Biopharma Stock on Monday?Benzinga · Mon, Sep 21, 2026
- Cue Biopharma, Inc.: Material event (8-K)SEC EDGAR · Mon, Sep 21, 2026
Congress activity
Disclosed STOCK Act trades in CUE
No recent disclosed trades by Congress in CUE. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in CUE · open-market 5 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Garzone Pamela Director · Common Stock · 2026-07-09 | Grant | 18.9K | — | 2026-07-09 | 2026-08-28 |
Sarraf Pasha Director · Common Stock · 2026-07-09 | Grant | 18.4K | — | 2026-07-09 | 2026-08-28 |
Meluzio Michael Vincent VP, Prin. Accounting Officer · Common Stock · 2026-08-13 | Exercise | 13.65K | — | 2026-08-13 | 2026-08-17 |
Ray Sumita Chief Legal Compliance Officer · Common Stock · 2026-08-13 | Exercise | 18.2K | — | 2026-08-13 | 2026-08-17 |
Ray Sumita Chief Legal Compliance Officer · Common Stock · 2026-08-13 | Sell | 2.38K | $70K | 2026-08-13 | 2026-08-17 |
Ray Sumita Chief Legal Compliance Officer · Common Stock · 2026-08-13 | Sell | 6.44K | $196K | 2026-08-13 | 2026-08-17 |
Ray Sumita Chief Legal Compliance Officer · Common Stock · 2026-08-13 | Sell | 4 | $125 | 2026-08-13 | 2026-08-17 |
Ray Sumita Chief Legal Compliance Officer · Common Stock · 2026-08-13 | Exercise | 18.2K | — | 2026-08-13 | 2026-08-17 |
Meluzio Michael Vincent VP, Prin. Accounting Officer · Common Stock · 2026-08-13 | Sell | 1.52K | $45K | 2026-08-13 | 2026-08-17 |
Meluzio Michael Vincent VP, Prin. Accounting Officer · Common Stock · 2026-08-13 | Sell | 4.11K | $125K | 2026-08-13 | 2026-08-17 |
SEC filings
EDGAR filings in CUE · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.